New collaborative effort aims to cure ALK-positive lung cancer
December 6, 2024
Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged between 20 and 50. Upon diagnosis, 80% of individuals already have stage 4 metastatic cancer, spread beyond the lungs to other parts of the body. Despite initially effective ALK inhibitor treatments, the cancer recurs in most patients, and there are about 70,000 people living with ALK+ lung cancer in the United States.
UPDATES AND NEWS
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer
Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab | The Cancer Letter
Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures.
Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial Targeting Residual Disease in AML
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 709.